Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can the way we talk about cancer change how we interact with the disease?

2.

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

3.

Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?

4.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors

5.

For MDS-Related Anemia, Telomerase Inhibitor Approved.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot